Ss Innovations International, INC 8-K filings

SS Innovations International, Inc. announced the departure of its Interim Chief Financial Officer, Arvind Palaniappan, with Dr. Vishwajyoti P. Srivastava assuming the role on an interim basis.

SS Innovations International, Inc. announced its CEO successfully completed the world's first intercontinental robotic cardiac telesurgery using the SSi Mantra 3 system, spanning over 4,000 miles from France to India.

SS Innovations International, Inc. announced a significant operational milestone, surpassing 100 installations of its SSi Mantra surgical robotic system across India and six other countries, with over 5,000 successful surgical procedures completed to date.

SS Innovations International, Inc. announced the successful completion of the world's first robotic telesurgery for weight loss using its SSi Mantra 3 system, bridging a distance of 560 miles with flawless precision.

SS Innovations International, Inc. announced the successful completion of the first robotic cardiac surgery in the Americas and Western Hemisphere using its SSi Mantra 3 surgical robotic system.

SS Innovations International, Inc. announced significant revenue growth in 2024 and Q1 2025, driven by increasing installations of its cost-effective SSi Mantra surgical robotic system, as it targets strategic global expansion into Europe and the United States.

SS Innovations International, Inc. announced it will ring the Nasdaq Opening Bell on June 3, 2025, celebrating its recent Nasdaq uplisting and the completion of over 4,000 robotic surgeries with its SSi Mantra system.

SS Innovations International, Inc. announced its SSi Mantra surgical robotic system has successfully performed over 4,000 robotic surgeries across more than one hundred types of procedures without complications, injuries, or mortalities.

SS Innovations International appoints Dr. Vishwajyoti P. Srivastava as CEO Asia Pacific and increases his base compensation to $300,000 annually.

SS Innovations International, Inc. announced a 40.8% increase in revenue to $5.1 million for the first quarter of 2025, driven by higher sales of the SSi Mantra 3 surgical robotic system.

SS Innovations International plans to submit a De Novo Classification Request to the FDA in July 2025 for its SSi Mantra 3 surgical robotic system.

SS Innovations International reiterates its first quarter 2025 guidance and reports a significant increase in orders for its SSi Mantra surgical robotic systems in April 2025.

SS Innovations International, Inc. announces a planned CFO transition with Anup Sethi stepping down and Arvind Palaniappan appointed as Interim CFO, effective May 1, 2025.

SS Innovations International, Inc. announces its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to commence on April 25, 2025, under the ticker symbol SSII.

SS Innovations reports significant milestones in 2024, including a four-fold revenue increase and expansion of its surgical robotic system installations, while projecting continued growth and regulatory approvals in the near future.

SS Innovations successfully performed India's first robotic cardiac telesurgery over a 2,000-kilometer distance, marking a significant advancement in accessible healthcare.

SS Innovations International, Inc. announced the unveiling of its Mobile Tele-Surgical Unit, SSI MantraM, at the Second Global Multi-Specialty Robotic Surgery Conference (SMRSC) in India, aiming to improve remote surgical access and healthcare delivery.

SS Innovations International announces its 2nd Global Multi-Specialty Robotic Surgery Conference (SMRSC 2025) in India, highlighting advancements in robotic surgery and the SSi Mantra 3 Surgical Robotic System.

SS Innovations International, Inc. has received $17 million in financing from its CEO, Dr. Sudhir Srivastava, through his holding company, with potential for additional funding to support expansion.

SS Innovations successfully performed the world's first robotic cardiac telesurgeries, demonstrating the potential of remote surgery with its SSi Mantra 3 system.

SS Innovations has completed a re-audit of its financial statements, withdrawn its S-1 registration, and is moving forward with plans to uplist to Nasdaq.

SS Innovations has become the first and only company in India to receive regulatory approval for Telesurgery and Teleproctoring capabilities for its SSi Mantra surgical robotic system.

SS Innovations successfully completed Indonesia's first robotic cardiac surgery using its SSi Mantra Surgical Robotic System, marking a significant advancement in the region's healthcare.

SS Innovations has appointed Tim Adams, a seasoned healthcare executive, to its Board of Directors as an Independent Director.

SS Innovations International Inc. announces the successful completion of over 2,000 robotic surgeries using its SSi Mantra Surgical Robotic System, primarily in India.

SS Innovations anticipates submitting an investigational device exemption application in the first quarter of 2025 and securing pre-market approvals by the end of 2025 for its SSi Mantra Surgical Robotic System.

SS Innovations International, Inc. has appointed Dr. Fredric Moll, the founder of Intuitive Surgical, as Vice Chairman of its Board of Directors.

SS Innovations has sold its first SSi Mantra Surgical Robotic System in South America, marking a significant step in its global expansion.

SS Innovations is restating past financials due to its previous auditor being barred by the SEC, leading to a temporary move to the Expert Market tier, while also adding two new independent directors.

SS Innovations International has appointed Dr. Frederic Moll and Timothy P. Adams to its board of directors, expanding it from five to seven members.